Becton Dickinson (BDX) announced it has received FDA 510(k) clearance for the BD Veritor System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors’ offices, urgent care centers, retail clinics and other convenient points of care.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson, BNY, Incyte, Duolingo, Jabil: Major Stock Sales Unveiled!
- Becton, Dickinson and Co’s PUREST Study: A New Era in Urine Management
- Becton Dickinson announces BD Libertas combination product clinical trial
- Cautious Hold Rating on Becton Dickinson Amid Uncertainties in Waters Merger and Revenue Projections
- DoorDash, Southwest downgraded: Wall Street’s top analyst calls